Program
Anti-B7-H4/MMAE ADC LNCB74
Its studies are mostly in Ovarian Neoplasms, led by LigaChem Biosciences.
Furthest: phase 1, since Jan 8, 20251 company-led study, 1 open or runningNext primary completion: Dec 2027 (phase 1)
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| LigaChem Biosciences | 11 open or running | phase 1since Jan 8, 2025 | Jan 8, 2025 | Dec 2027phase 1 · NCT06774963 |
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Jan 8, 2025First study: phase 1 study in Ovarian NeoplasmsFirst studyNCT06774963 · 145 planned · United States
Ahead
- Dec 2027Primary completion: phase 1 study in Ovarian NeoplasmsNCT06774963
TargetBeta
VTCN1 →read by rule
“An antibody-drug conjugate (ADC) composed of a human immunoglobulin (Ig) G1 kappa monoclonal antibody directed against the T-cell checkpoint ligand B7-H4 (V-set domain-containing T-cell activation inhibitor 1; VTCN1; B7x; B7S1) ”NCIt, by rule
Other programs on VTCN1
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| mocertatug rezetecan | GlaxoSmithKline | phase 3 | 11 |
| Anti-B7-H4 Antibody Drug Conjugate BG-C9074rule | BeOne Medicines | phase 3 | 2 |
| puxitatug samrotecan | AstraZeneca | phase 3 | 2 |
| Anti-B7-H4/Anti-4-1BB Bispecific Antibody ABL103rule | abl-bio-inc | phase 2 | 2 |
Studies
All 1 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT06774963Ovarian Neoplasms · United States | 1 | Recruiting | Dec 2027 | 145 |
How it is read
Names in the registry
- “LNCB74”, 1 entry
Conditions, from the studies’ own filings
- Ovarian Neoplasms, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.